Early progression of Krabbe disease in patients with symptom onset between 0 and 5 months
Maria L Beltran-Quintero, Nicholas A Bascou, Michele D Poe, David A Wenger, Carlos A Saavedra-Matiz, Matthew J Nichols, Maria L Escolar, Maria L Beltran-Quintero, Nicholas A Bascou, Michele D Poe, David A Wenger, Carlos A Saavedra-Matiz, Matthew J Nichols, Maria L Escolar
Abstract
Background: Krabbe disease is a rare neurological disorder caused by a deficiency in the lysosomal enzyme, β-galactocerebrosidase, resulting in demyelination of the central and peripheral nervous systems. If left without treatment, Krabbe disease results in progressive neurodegeneration with reduced quality of life and early death. The purpose of this prospective study was to describe the natural progression of early onset Krabbe disease in a large cohort of patients.
Methods: Patients with early onset Krabbe disease were prospectively evaluated between 1999 and 2018. Data sources included diagnostic testing, parent questionnaires, standardized multidisciplinary neurodevelopmental assessments, and neuroradiological and neurophysiological tests.
Results: We evaluated 88 children with onset between 0 and 5 months. Median age of symptom onset was 4 months; median time to diagnosis after onset was 3 months. The most common initial symptoms were irritability, feeding difficulties, appendicular spasticity, and developmental delay. Other prevalent symptoms included axial hypotonia, abnormal deep tendon reflexes, constipation, abnormal pupillary response, scoliosis, loss of head control, and dysautonomia. Results of nerve conduction studies showed that 100% of patients developed peripheral neuropathy by 6 months of age. Median galactocerebrosidase enzyme activity was 0.05 nmol/h/mg protein. The median survival was 2 years.
Conclusions: This is the largest prospective natural history study of Krabbe disease. It provides a comprehensive description of the disease during the first 2 years of life. With recent inclusion of state mandated newborn screening programs and promising therapeutic interventions, enhancing our understanding of disease progression in early onset Krabbe disease will be critical for developing treatments, designing clinical trials, and evaluating outcomes.
Keywords: Early-infantile; Globoid cell leukodystrophy; Infantile; Krabbe disease; Natural history; Newborn screening.
Conflict of interest statement
Ethics approval and consent to participateAll research was conducted with the approval of the institutional review boards (IRB) from the University of North Carolina (IRB-08-0237) and the University of Pittsburgh (IRB-PRO11050036).
Consent for publicationApproval was granted by the institutional review boards (IRB) from the University of North Carolina (IRB-08-0237) and the University of Pittsburgh (IRB-PRO11050036).
Competing interestsThe authors declare that they have no competing interests.
Publisher’s NoteSpringer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Figures
References
- Wenger DA, Rafi MA, Luzi P, et al. Krabbe disease: genetic aspects and progress toward therapy. Mol Genet Metab. 2000;70:1–9. doi: 10.1006/mgme.2000.2990.
- Zafeiriou DI, Anastasiou AL, Michelakaki EM, Augoustidou-Savvopoulou PA, Katzos GS, Kontopoulos EE. Early-infantile Krabbe disease: deceptively normal magnetic resonance imaging and serial neurophysiological studies. Brain and Development. 1997;19(7):488–491. doi: 10.1016/S0387-7604(97)00049-1.
- Wraith JE. The clinical presentation of lysosomal storage disorders. Acta Neurol Taiwanica. 2004;13(3):101–106.
- Suzuki K. Globoid cell leukodystrophy (Krabbe’s disease): update. J Child Neurol. 2003;18(9):595–603. doi: 10.1177/08830738030180090201.
- Hagberg B, Sourander P, Svennerholm L. Diagnosis of Krabbe’s infantile leucodystrophy. J Neurol Neurosurg Psychiatry. 1963;26:195–198. doi: 10.1136/jnnp.26.3.195.
- Sakai N. Pathogenesis of leukodystrophy for Krabbe disease: molecular mechanism and clinical treatment. Brain and Development. 2009;31(7):485–487. doi: 10.1016/j.braindev.2009.03.001.
- Brodsky MC, Hunter JS. Positional ocular flutter and thickened optic nerves as sentinel signs of Krabbe disease. J AAPOS. 2011;15(6):595–597. doi: 10.1016/j.jaapos.2011.05.024.
- Morse LE, Rosman NP. Myoclonic seizures in Krabbe disease: a unique presentation in late-onset type. Pediatr Neurol. 2006;35(2):154–157. doi: 10.1016/j.pediatrneurol.2006.02.004.
- Lyon G, Hagberg B, Evrard PH, Allaire C, Pavone L, Vanier M. Symptomatology of late onset Krabbe’s leukodystrophy: the European experience. Dev Neurosci. 1991;13(4–5):240–244. doi: 10.1159/000112167.
- Barone R, Brühl K, Stoeter P, Fiumara A, Pavone L, Beck M. Clinical and neuroradiological findings in classic infantile and late-onset globoid-cell leukodystrophy (Krabbe disease) Am J Med Genet Part A. 1996;63(1):209–217. doi: 10.1002/(SICI)1096-8628(19960503)63:1<209::AID-AJMG37>;2-Q.
- Shao Y, Choquet K, Piana RL, et al. B. Mutations in GALC cause late-onset Krabbe disease with predominant cerebellar ataxia. Neurogenetics. 2016;17(2):137–141. doi: 10.1007/s10048-016-0476-2.
- Moser HW. Peripheral nerve involvement in Krabbe disease: a guide to therapy selection and evaluation. Neurology. 2006;67:201–202. doi: 10.1212/01.wnl.0000231531.73713.a9.
- Wenger DA, Suzuki K, Suzuki Y, Suzuki K. Galactosylceramide lipidosis: globoid cell leukodystrophy (Krabbe disease). In: Scriver CR, Sly WS, Childs B et al. The metabolic and molecular bases of inherited disease. 8th ed. New York, NY: McGraw-Hill, 2001;3669–3694.
- Duffner PK, Jalal K, Carter RL. The Hunter’s Hope Krabbe family database. Pediatr Neurol. 2009;40(1):13–18. doi: 10.1016/j.pediatrneurol.2008.08.011.
- Zhao S, Zhan X, Wang Y, Ye J, Han L, Qiu W, Gao X, Gu X, Zhang H. Large-scale study of clinical and biochemical characteristics of Chinese patients diagnosed with Krabbe disease. Clin Genet. 2017.
- Escolar ML, Poe MD, Provenzale JM, et al. Transplantation of umbilical-cord blood in babies with infantile Krabbe’s disease. New Engl J Med. 2005;352(20):2069–2081. doi: 10.1056/NEJMoa042604.
- Lim ZY, Ho AY, Abrahams S, et al. Sustained neurological improvement following reduced-intensity conditioning allogenic hematopoietic stem cell transplantation for late-onset Krabbe disease. Bone Marrow Transpl. 2008:1–2.
- Escolar ML, Yelin K, Poe MD. Neurodevelopmental outcomes of children with infantile Krabbe disease treated with umbilical cord blood transplantation: 10 years of follow up. CML: Lysosomal Storage Disease. 2006;6(3):72–79.
- Escolar ML, Poe MD, Martin HR, Kurtzberg J. A staging system for infantile Krabbe disease to predict outcome after unrelated umbilical cord blood transplantation. Pediatrics. 2006;118(3):e879–e889. doi: 10.1542/peds.2006-0747.
- Wright MD, Poe MD, DeRenzo A, Haldal S, Escolar ML. Developmental outcomes of cord blood transplantation for Krabbe disease a 15-year study. Neurology. 2017;89(13):1365–1372. doi: 10.1212/WNL.0000000000004418.
- Lantos JD. Dangerous and expensive screening and treatment for rare childhood diseases: the case of krabbe disease. Developmental Disabilities Research Reviews. 2011;17(1):15–18. doi: 10.1002/ddrr.133.
- Orsini JJ, Saavedra-Matiz CA, Gelb MH, Caggana M. Newborn screening for Krabbe's disease. J Neurosci Res. 2016;94(11):1063–1075. doi: 10.1002/jnr.23781.
- Wasserstein MP, Andriola M, Arnold G, Aron A, Duffner P, Erbe RW, Escolar ML, Estrella L, Galvin-Parton P, Iglesias A, Kay DM. Clinical outcomes of children with abnormal newborn screening results for Krabbe disease in New York state. Genetics in Medicine. 2016;18(12):1235. doi: 10.1038/gim.2016.35.
- Kwon JM, Matern D, Kurtzberg J, Wrabetz L, Gelb MH, Wenger DA, Ficicioglu C, Waldman AT, Burton BK, Hopkins PV, Orsini JJ. Consensus guidelines for newborn screening, diagnosis and treatment of infantile Krabbe disease. Orphanet journal of rare diseases. 2018;13(1):30. doi: 10.1186/s13023-018-0766-x.
- Escolar ML, Kiely B, Shawgo, et al. Psychosine, a marker of Krabbe phenotype and treatment effect. Mol Genet Metab. 2017;121(3):271–278. doi: 10.1016/j.ymgme.2017.05.015.
- Biffi A, Aubourg P, Cartier N. Gene therapy for leukodystrophies. Hum Mol Genet. 2011;20(1):R42–R53. doi: 10.1093/hmg/ddr142.
- Krabbe K. A new familial, infantile form of diffuse brain-sclerosis. Brain. 1916;39(1–2):74–114. doi: 10.1093/brain/39.1-2.74.
- Hagberg B, Kollberg H, Sourander P, Akesson HO. Infantile globoid cell leukodystrophy (Krabbe’s disease): a clinical and genetic study of 32 Swedish cases 1953-1967. Neuropadiatrie. 1969;1:74–88. doi: 10.1055/s-0028-1091865.
- Duffner PK, Barczykowski A, Jalal K, Yan L, Kay DM, Carter RL. Early infantile Krabbe disease: results of the world-wide Krabbe registry. Pediatr Neurol. 2011;45(3):141–148. doi: 10.1016/j.pediatrneurol.2011.05.007.
- Duffner PK, Barczykowski A, Kay DM, Jalal K, Yan L, Abdelhalim A, Gill S, Gill AL, Carter R. Later onset phenotypes of Krabbe disease: results of the world-wide registry. Pediatr Neurol. 2012;46(5):298–306.190. doi: 10.1016/j.pediatrneurol.2012.02.023.
- Bascou N, Derenzo A, Poe MD, Escolar ML. A prospective natural history study of Krabbe disease in a patient cohort with onset between 6 months and 3 years of life. Orphanet J Rare Dis. 2018.
- Kuczmarski RJ, Ogden CL, Guo SS, et al. 2000 CDC growth charts for the United States: methods and development. National Center for Health Statistics. Vital Health Stat 2002;11:1.
- Martin HR, Poe MD, Reinhartsen D, et al. Methods for assessing neurodevelopment in lysosomal storage diseases and related disorders: a multidisciplinary perspective. Acta Paediatr Suppl. 2008;97:69–75. doi: 10.1111/j.1651-2227.2008.00651.x.
- Bruininks RH, Woodcock RW, Weatherman RF, Hill BK. Scales of Independent Behavior-Revised. Itasca, IL: Riverside Publishing. 1996.
- Folio, M. Rhonda, and Rebecca R. Fewell. Peabody developmental motor scales. Pro-Ed, 2000.
- Mullen, E. M. Mullen scales of early learning AGS edition. American Guidance Service. Inc., Circle Pines. 1995.
- Russell DJ, Rosenbaum PL, Wright M, Avery LM. 2013. Gross motor function measure (GMFM-66 and GMFM-88) User's manual, 2nd Edition. Mac Keith Press.
- Shah SS, Ebberson J, Kestenbaum LA, Hodinka RL, Zorc JJ. Age-specific reference values for cerebrospinal fluid protein concentration in neonates and young infants. J Hosp Med. 2011.
- Wong M, Schlaggar BL, Buller RS, Storch GA, Landt M. Cerebrospinal fluid protein concentration in pediatric patients: defining clinically relevant reference values. Arch Pediatr Adolesc Med. 2000.
- Saavedra-Matiz CA, Isabelle JT, Biski CK, Duva SJ, Sweeney ML, Parker AL, et al. Cost-effective and scalable DNA extraction method from dried blood spots. Clin Chem. 2013.
- Aldosari M, Altuwaijri M, Husain AM. Brain-stem auditory and visual evoked potentials in children with Krabbe disease. Clin Neurophysiol. 2004;115(7):1653–1656. doi: 10.1016/j.clinph.2004.02.022.
- Husain AM, Altuwaijri M, Aldosari M. Krabbe disease neurophysiologic studies and MRI correlations. Neurology. 2004;63(4):617–620. doi: 10.1212/01.WNL.0000134651.38196.F8.
- Manfredi MA. Epidemiology of gastroesophageal reflux disease. In: Till H, Thomson M, Foker J, Holcomb G III, Khan K, editors. Esophageal and gastric disorders in infancy and childhood. Berlin, Heidelberg: Springer; 2017.
- Sherman Philip M, Hassall E, Fagundes-Neto U, Gold Benjamin D, Kato S. A Global, Evidence-based consensus on the definition of gastroesophageal reflux disease in the pediatric population. Am J Gastroenterol. 2009;104:1278–1295. doi: 10.1038/ajg.2009.129;publishedonline7April2009.
- Gupta A, Poe MD, Styner MA, Panigrahy A, Escolar ML. Regional differences in fiber tractography predict neurodevelopmental outcomes in neonates with infantile Krabbe disease. Neuroimage Clin. 2014;7:792–798. doi: 10.1016/j.nicl.2014.09.014.
- Wolke D, Bilgin A, Samara M. Systematic review and meta-analysis: fussing and crying durations and prevalence of colic in infants. J Pediatr. 2017;185:55–61. doi: 10.1016/j.jpeds.2017.02.020.
- Saavedra-Matiz CA, Luzi P, Nichols M, Orsini JJ, Caggana M, Wenger DA. Expression of individual mutations and haplotypes in the galactocerebrosidase gene identified by the newborn screening program in New York state and in confirmed cases of Krabbe’s disease. J Neurosci Res. 2016.
- Wenger DA, Luzi P, Rafi MA. Krabbe disease: are certain mutations disease-causing only when specific polymorphisms are present or when inherited in trans with specific second mutations? Mol Genet Metab. 2014.
Source: PubMed